CheckMate 274: Adjuvant nivolumab ups DFS in high-risk bladder cancer
Treatment with the PD-1 immune checkpoint inhibitor nivolumab after radical surgery significantly extends disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence, regardless of their PD-L1 status, according to the CheckMate 274 study presented at the 2021 ASCO GUCS.
